Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 7.046
Filter
1.
Front Endocrinol (Lausanne) ; 15: 1282925, 2024.
Article in English | MEDLINE | ID: mdl-38567303

ABSTRACT

Background: Encapsulating peritoneal sclerosis (EPS) is a rare complication of prolonged peritoneal dialysis (PD) exposure, characterised by peritoneal thickening, calcification, and fibrosis ultimately presenting with life-threatening bowel obstruction. The presence or role of peritoneal calcification in the pathogenesis of EPS is poorly characterised. We hypothesise that significantly aberrant bone mineral metabolism in patients on PD can cause peritoneal calcification which may trigger the development of EPS. We compared the temporal evolution of bone mineral markers during PD in EPS patients with non-EPS long-term PD controls. Methods: Linear mixed model and logistic regression analysis were used to compare four-monthly serum levels of calcium, phosphate, parathyroid hormone, and alkaline phosphatase (ALP) over the duration of PD exposure in 46 EPS and 46 controls (PD, non-EPS) patients. Results: EPS patients had higher mean calcium (2.51 vs. 2.41 mmol/L) and ALP (248.00 vs. 111.13 IU/L) levels compared with controls (p=0.01 and p<0.001 respectively, maximum likelihood estimation). Logistic regression analysis demonstrated that high serum calcium and phosphate levels during PD were associated with a 4.5 and 2.9 fold increase in the risk of developing EPS respectively. Conclusion: High levels of calcium and phosphate in patients on PD were identified to be risk factors for EPS development. Possible reasons for this may be an imbalance of pro-calcifying factors and calcification inhibitors promoting peritoneal calcification which increases peritoneal stiffness. Mechanical alterations may trigger, unregulated fibrosis and subsequent development of EPS. Improved management of secondary hyperparathyroidism during PD may ultimately diminish the EPS risk.


Subject(s)
Calcinosis , Hyperparathyroidism , Peritoneal Fibrosis , Humans , Peritoneal Fibrosis/etiology , Calcium , Risk Factors , Calcinosis/etiology , Minerals , Phosphates
2.
Acta Ortop Mex ; 38(1): 57-59, 2024.
Article in English | MEDLINE | ID: mdl-38657153

ABSTRACT

Acute calcific periarthritis (ACP) in the interphalangeal joints of the hand is rare, with less than 100 cases reported. A rare case of ACP in a proximal interphalangeal (PIP) joint of the hand, in a young black woman, after acute trauma, is presented. She experienced severe pain and limited range of motion, and was medicated with an oral corticoid, which was followed by a rapid resolution of the symptoms. At six months, there were no signs of clinical or radiographic recurrence. Recognition of ACP allows for avoiding unnecessary treatments. In this case, treatment with corticoids might have played a role in a faster recovery.


La periartritis calcificada aguda (PCA) en las articulaciones interfalángicas de la mano es rara, con menos de 100 casos reportados. Se presenta un caso raro de PCA en una articulación interfalángica proximal (IFP) de la mano, en una mujer joven de raza negra, después de un traumatismo agudo. Experimentó dolor intenso y rango de movimiento limitado, y fue medicada con un corticoide oral, lo que fue seguido por una rápida resolución de los síntomas. A los seis meses no hubo signos de recurrencia clínica ni radiológica. El reconocimiento de PCA permite evitar tratamientos innecesarios. En este caso, el tratamiento con corticoides podría haber contribuido a una recuperación más rápida.


Subject(s)
Calcinosis , Finger Joint , Periarthritis , Humans , Female , Calcinosis/etiology , Acute Disease , Finger Injuries , Adult
3.
Endocr Regul ; 58(1): 101-104, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-38656253

ABSTRACT

Diabetes mellitus type 3 refers to diabetes secondary to an existing disease or condition of the exocrine pancreas and is an uncommon cause of diabetes occurring due to pancreatogenic pathology. It accounts for 15-20% of diabetic patients in Indian and Southeast Asian continents. This is case report of a rare case of type 3 diabetes mellitus (T3DM) presenting with diabetic ketoacidosis (DKA). The patient was admitted for DKA along with complaint of hyperglycemia, blood glucose of 405 mg/dl with HbA1c level of 13.7%. Computed tomography evidence revealed chronic calcific pancreatitis with intraductal calculi and dilated pancreatic duct.


Subject(s)
Calcinosis , Calculi , Diabetic Ketoacidosis , Pancreatic Ducts , Pancreatitis, Chronic , Humans , Diabetic Ketoacidosis/complications , Diabetic Ketoacidosis/diagnosis , Pancreatitis, Chronic/complications , Pancreatitis, Chronic/diagnosis , Pancreatitis, Chronic/diagnostic imaging , Calculi/complications , Calculi/diagnostic imaging , Calculi/diagnosis , Pancreatic Ducts/pathology , Pancreatic Ducts/diagnostic imaging , Calcinosis/etiology , Calcinosis/diagnosis , Calcinosis/complications , Calcinosis/diagnostic imaging , Male , Adult , Tomography, X-Ray Computed
4.
Medicina (Kaunas) ; 60(3)2024 Feb 26.
Article in English | MEDLINE | ID: mdl-38541125

ABSTRACT

Introduction: Symptomatic calcifications of the breast or skin after breast cancer surgery and adjuvant radiotherapy are a rare entity, with only a few case reports published worldwide, reducing the patient's quality of life, whilst asymptomatic calcifications are a common finding on imaging methods. Case presentation: Herein, we present a rare case report of calcifications after mastectomy and post-mastectomy radiation therapy causing chronic inflammation with ulceration and fistula formation, with a two-step surgical approach consisting of excision with linear suture and excision with the reconstruction using a thoraco-epigastric flap. Conclusions: To our knowledge, this is the first publication proving the feasibility of this therapy in patients with symptomatic dystrophic calcifications of the skin or the breast. Moreover, the article provides an up-to-date review of published studies about symptomatic calcifications after breast cancer surgery and radiotherapy with a focus on the time of the clinical manifestation from the radiotherapy and the used radiotherapy scheme.


Subject(s)
Breast Neoplasms , Calcinosis , Mammaplasty , Humans , Female , Mastectomy/adverse effects , Mastectomy/methods , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Mammaplasty/methods , Quality of Life , Breast/surgery , Calcinosis/etiology , Calcinosis/surgery , Radiotherapy, Adjuvant
5.
JAMA Ophthalmol ; 142(3): e234841, 2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38512158

ABSTRACT

This case report describes a diagnosis of dystrophic calcification of a silicone intraocular lens implant in a patient who presented with foggy vision and glare.


Subject(s)
Calcinosis , Choristoma , Lenses, Intraocular , Humans , Lenses, Intraocular/adverse effects , Calcinosis/diagnostic imaging , Calcinosis/etiology
6.
BMC Womens Health ; 24(1): 187, 2024 Mar 20.
Article in English | MEDLINE | ID: mdl-38509531

ABSTRACT

BACKGROUND: Residual microcalcifications after neoadjuvant chemotherapy (NAC) are challenging for deciding extent of surgery and questionable for impact on prognosis. We investigated changes in the extent and patterns of microcalcifications before and after NAC and correlated them with pathologic response. We also compared prognosis of patients depending on presence of residual microcalcifications after NAC. METHODS: A total of 323 patients with invasive breast carcinoma treated with neoadjuvant chemotherapy at Kangbuk Samsung Hospital and Samsung Medical center from March 2015 to September 2018 were included. Patients were divided into four groups according to pathologic response and residual microcalcifications. Non-pCRw/mic group was defined as breast non-pCR with residual microcalcifications. Non-pCRw/o mic group was breast non-pCR without residual microcalcifications. pCRw/mic group was breast pCR with residual microcalcifications. pCRw/o mic group was breast pCR without residual microcalcifications. The first aim of this study is to investigate changes in the extent and patterns of microcalcifications before and after NAC and to correlate them with pathologic response. The second aim is to evaluate oncologic outcomes of residual microcalcifications according to pathologic response after NAC. RESULTS: There were no statistical differences in the extent, morphology, and distribution of microcalcifications according to pathologic response and subtype after NAC (all p > 0.05). With a median follow-up time of 71 months, compared to pCRw/o mic group, the hazard ratios (95% confidence intervals) for regional recurrence were 5.190 (1.160-23.190) in non-pCRw/mic group and 5.970 (1.840-19.380) in non-pCRw/o mic group. Compared to pCRw/o mic group, the hazard ratios (95% CI) for distant metastasis were 8.520 (2.130-34.090) in non-pCRw/mic group, 9.120 (2.850-29.200) in non-pCRw/o mic group. Compared to pCRw/o mic, the hazard ratio (95% CI) for distant metastasis in pCRw/mic group was 2.240 (0.230-21.500) without statistical significance (p = 0.486). CONCLUSIONS: Regardless of residual microcalcifications, patients who achieved pCR showed favorable long term outcome compared to non-pCR group.


Subject(s)
Breast Neoplasms , Calcinosis , Humans , Female , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Neoadjuvant Therapy/adverse effects , Prognosis , Breast/pathology , Calcinosis/diagnostic imaging , Calcinosis/drug therapy , Calcinosis/etiology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant , Retrospective Studies
8.
Semin Arthritis Rheum ; 66: 152431, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38537324

ABSTRACT

In SSc, dystrophic calcinosis is one of the major clinical manifestations, characterized by the deposition of insoluble calcific substances in tissues, predominantly in the chemical form of calcium hydroxyapatite. Furthermore, calcinosis might lead to compressive neuropathies and severe pain. Current evidence suggests that tissue ischemia and repeated trauma are implicated in the development of calcinosis; however, there are still too many unknown areas that need to be investigated. Detection of calcinosis is commonly performed using X-ray or ultrasound. Moreover, quantification of calcinosis with X-ray and dual-energy computed tomography might be useful for the assessment of disease burden and monitoring of the disease. Despite its prevalence and clinical outcomes, there are no approved disease-modifying treatments for calcinosis in SSc. Debulking or surgical intervention might be preferred for calcinosis complicated with infection, compressive symptoms, or relief of pain. Therefore, innovative investigations and tailored therapeutic approaches are urgently needed to lift the burden of calcinosis from the hands of SSc patients.


Subject(s)
Calcinosis , Scleroderma, Systemic , Humans , Calcinosis/etiology , Calcinosis/diagnostic imaging , Calcinosis/therapy , Scleroderma, Systemic/complications
9.
World J Surg ; 48(5): 1209-1218, 2024 May.
Article in English | MEDLINE | ID: mdl-38470437

ABSTRACT

BACKGROUND: Anastomotic leak is one of the most feared complications of esophagectomy. Previous studies have suggested a potential link between aortic calcifications detected on routine preoperative CT scans and increased risk of anastomotic leak after esophagectomy. This study aims to investigate whether clinicians' assessment of aortic calcifications can predict the occurrence of anastomotic leaks in patients undergoing esophagectomy for cancer. METHODS: A long-term follow-up was conducted on consecutive patients with esophageal cancer who underwent elective open esophagectomy at a Finnish tertiary hospital. Aortic calcifications were evaluated based on CT scans and categorized on a 0-3 scale reflecting the number of calcifications in the affected segment of the aorta. Reviewers assessing the calcifications were blinded to clinical details and postoperative outcomes. RESULTS: The study included 97 patients (median age: 64 years and range: 43-78; 20% female), with a median follow-up time of 1307 (2-1540) days. Among them, 22 patients (23%) had postoperative anastomotic leak. We observed a significant association between calcifications in the descending aorta and a higher risk of anastomotic leak (p = 0.007), as well as an earlier occurrence of leak postoperatively (p = 0.013). However, there was no association between aortic calcifications and increased mortality. CONCLUSIONS: Presence of calcifications in the descending aorta is independently associated with an increased risk of anastomotic leaks following esophagectomy for cancer. Identifying patients at higher risk for this complication could facilitate appropriate pre- and postoperative interventions, as well as enable earlier diagnosis and treatment to mitigate the severity of the complication.


Subject(s)
Anastomotic Leak , Aorta, Thoracic , Esophageal Neoplasms , Esophagectomy , Humans , Esophagectomy/adverse effects , Female , Middle Aged , Male , Anastomotic Leak/etiology , Anastomotic Leak/diagnostic imaging , Anastomotic Leak/epidemiology , Esophageal Neoplasms/surgery , Aged , Aorta, Thoracic/diagnostic imaging , Aorta, Thoracic/surgery , Adult , Follow-Up Studies , Tomography, X-Ray Computed , Vascular Calcification/diagnostic imaging , Vascular Calcification/etiology , Aortic Diseases/surgery , Aortic Diseases/etiology , Aortic Diseases/diagnostic imaging , Retrospective Studies , Calcinosis/diagnostic imaging , Calcinosis/etiology
13.
BMC Cardiovasc Disord ; 24(1): 34, 2024 01 06.
Article in English | MEDLINE | ID: mdl-38184530

ABSTRACT

Coronary heavy calcification (HC) poses a sturdy challenge to percutaneous coronary intervention (PCI). Scores considering calcification length, thickness, or circumferential extent, are widely accepted to dictate upfront calcium modification to improve PCI outcomes. Although often marginalized, calcification shape (morphology) may require consideration during procedure planning in selected cases. This case demonstrates how a focal but spur-shaped calcification led to a massive proximal left anterior descending (LAD) dissecting intramural hematoma.


Subject(s)
Calcinosis , Percutaneous Coronary Intervention , Humans , Calcium , Percutaneous Coronary Intervention/adverse effects , Tunica Intima , Coronary Vessels/diagnostic imaging , Coronary Vessels/surgery , Calcinosis/diagnostic imaging , Calcinosis/etiology , Calcinosis/surgery , Hematoma/diagnostic imaging , Hematoma/etiology , Hematoma/therapy
14.
Pediatr Rheumatol Online J ; 22(1): 2, 2024 Jan 02.
Article in English | MEDLINE | ID: mdl-38166943

ABSTRACT

BACKGROUND: Juvenile Dermatomyositis (JDM) is a rare autoimmune disorder that primarily affects muscles and skin. One of the severe complications associated with JDM is calcinosis, and treating this condition presents significant challenges. This study aimed to evaluate the efficacy and safety of local injection of infliximab into calcinosis lesions in patients with JDM. METHODS: In this clinical trial, five patients diagnosed with JDM and calcinosis lesions were enrolled. The primary treatment consisted of weekly infliximab injections for 16 weeks, targeting all four sides of each lesion. Lesion dimensions, including length and width, were documented and monitored weekly. Before the intervention, patients underwent radiographic imaging. After the final injection in week 16, a follow-up radiographic assessment was performed. Data were analyzed using the Generalized Estimating Equation (GEE) method. RESULTS: The lesions' size significantly decreased in both length and width during each visit. On average, the lesion length reduced by 2.66%, and the width shrank by 3.32% per visit. Based on radiographic findings, the average length and width of lesions at the initial visit were 12.09 ± 5.05 mm (range: 6.00-25.50 mm) and 6.35 ± 3.00 mm (range: 2.00-16.00 mm), respectively. The average length and width at the last visit were 5.59 ± 7.05 mm (range: 0-23.00 mm) and 3.41 ± 4.05 mm (range: 0-13.00 mm), respectively. No specific side effects related to the treatment were reported. CONCLUSIONS: The results suggest that the direct administration of infliximab into the calcinosis lesions of patients with JDM could be a safe and effective treatment approach. TRIAL REGISTRATION: Name of the registry: The effect of infliximab injection into calcinosis lesions on patients with juvenile dermatomyositis (JDM), Trial registration number: IRCT20210808052107N1, Registration date: 2022-07-22, URL of trial registry record: https://en.irct.ir/trial/58329 .


Subject(s)
Calcinosis , Dermatomyositis , Humans , Dermatomyositis/complications , Dermatomyositis/drug therapy , Dermatomyositis/diagnosis , Infliximab/therapeutic use , Skin , Injections , Calcinosis/diagnostic imaging , Calcinosis/drug therapy , Calcinosis/etiology
16.
Curr Rheumatol Rep ; 26(2): 53-68, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38060107

ABSTRACT

PURPOSE OF REVIEW: We performed a systematic review of the literature on the epidemiology, pathogenesis, clinical and laboratory characterization, and treatment of calcinosis in patients with juvenile dermatomyositis (JDM). A qualitative systematic review was conducted from January 1975 to April 2023 according to the PRISMA protocol using three electronic databases: PubMed, Web of Science, and Scopus. Studies were analyzed based on the following eligibility criteria: at least one combination of the terms described in the search strategy appeared in the title, written in English, Portuguese, or Spanish, and addressed the epidemiology, pathogenesis, diagnosis, and treatment of calcinosis in juvenile dermatomyositis. Systematic or scoping reviews, letters, clinical images, book chapters, abstracts, inflammatory myopathy in other connective tissue diseases, idiopathic inflammatory myopathies in adults, and purely qualitative studies were excluded. RECENT FINDINGS: Seventy-five studies were included. According to the literature, calcinosis is common in women, around five years old, with three years of disease in association with osteoarticular, cutaneous, pulmonary manifestations, and fever. The pathogenesis is still unknown, but the participation of interleukin 1 and 6, tumor necrosis factor alpha, and innate immunity dysregulation seem to be involved. Common autoantibodies are anti-NXP-2, anti-MDA-5, and anti-Mi-2, and their treatment remains controversial. Prospective, randomized, controlled studies are needed to evaluate treatment protocols and map the natural history of this serious complication. Calcinosis seems to be more common in White female children with muscle weakness, fever, arthritis, severe pulmonary, and skin involvement with anti-NXP-2, anti-MDA-5, and anti-Mi-2 autoantibodies. The multitargets and aggressive treatment is recommended.


Subject(s)
Calcinosis , Dermatomyositis , Myositis , Child , Adult , Humans , Female , Child, Preschool , Dermatomyositis/complications , Dermatomyositis/epidemiology , Dermatomyositis/therapy , Prospective Studies , Autoantibodies , Myositis/complications , Calcinosis/epidemiology , Calcinosis/etiology , Calcinosis/therapy
17.
Trop Doct ; 54(2): 147-148, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38093193

ABSTRACT

Abdominal wall calcification in a peritoneal dialysis patient has not previously been reported. We describe a 40-year-old lady, a type 2 diabetic and hypertensive for the past 14 years, who did not have any history, clinical features or laboratory results suggesting autoimmune disease, and had not suffered from tuberculosis in the past, but who had been diagnosed with chronic kidney disease in 2016. She had initiated peritoneal dialysis in December 2018.


Subject(s)
Abdominal Wall , Calcinosis , Hyperparathyroidism, Secondary , Kidney Failure, Chronic , Peritoneal Dialysis , Female , Humans , Adult , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/therapy , Hyperparathyroidism, Secondary/diagnosis , Peritoneal Dialysis/adverse effects , Calcinosis/diagnosis , Calcinosis/etiology
18.
Int J Rheum Dis ; 27(1): e14859, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37540105

ABSTRACT

Abdominal aortic aneurysms (AAA) are rare in Behçet syndrome (BS) but may result in life-threatening complications. AAA are generally treated with surgical intervention following aggressive immunosuppressive therapy. Healing with wall calcification and mural thrombus for AAA is scarcely reported in the literature. Herein, we present a female patient who developed a large saccular aneurysm in the infra-renal abdominal aorta 6 months after the diagnosis. Endovascular intervention was not found to be possible because of the dimensions of the aneurysm and the patient did not consent for open surgery. Therefore, she received only immunosuppressive treatment. By the second year of follow-up, we detected reduction in the size of AAA, along with circumferential wall calcification and mural thrombus. The patient was followed-up for 20 years without rupture and currently doing well. This case demonstrates that calcified large saccular AAA might not necessitate surgical intervention and be followed-up for many years without any complication.


Subject(s)
Aortic Aneurysm, Abdominal , Behcet Syndrome , Calcinosis , Thrombosis , Humans , Female , Behcet Syndrome/complications , Behcet Syndrome/diagnosis , Behcet Syndrome/drug therapy , Follow-Up Studies , Aortic Aneurysm, Abdominal/diagnostic imaging , Aortic Aneurysm, Abdominal/etiology , Aortic Aneurysm, Abdominal/surgery , Immunosuppressive Agents/therapeutic use , Calcinosis/diagnostic imaging , Calcinosis/etiology , Calcinosis/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...